FILLING THE GAPActivity Report 2016

32

Mission

We are a not-for-profit consortium active in early research whose mission is to fund the development of breakthrough technologies that significantly enhance biopharmaceutical R&D productivity and accelerate the discovery and development of new medicines.

We have the capacity to fund SMEs and academic institutions across Canada. The best industrial research projects are selected through a rigorous evaluation process organized within open calls for proposals.

We strengthen Canada’s leadership in biopharmaceutical research by building on synergies between the pharma industry, SMEs and academia and fostering strong research networks locally and internationally. We open new avenues for translational research to answer unmet and complex medical needs while generating significant economic benefits for Quebec and Canada.

Business model

We have created an open innovation concept where 9 leading pharmaceutical companies along with the Canadian and Quebec governments collaborate and share the cost and benefits of research. Moreover, we secure additional funding by involving strategic research partners from Canada, the United States and Europe.

Our unique collaborative approach generates an impressive financial leverage (up to 25 fold) to fund the development of high-risk high-reward technologies, thereby bridging the gap in the innovation chain by derisking early stage research.

“We believe that the path to finding real solutions to complex diseases is through strong multi-disciplinary, multi-institutional public-private partnerships.”

- Diane Gosselin, President and CEO of CQDM

WHO WE ARE

While academic research typically focuses on generating knowledge, translational research which seeks to commercialize products and services is blocked by the scarcity of available funding dedicated to early stage applied research. CQDM made a bold and unprecedented commitment to fill that gap by supporting early translationalresearch that could not be otherwise funded by alternative sources. It also catalyzes technological maturation withinacademia in collaboration with start-ups or SMEs. CQDM funding is intended to derisk high value innovative technologies and generate a deal flow for seed funds and venture capital investors.

Moreover, CQDM is also filling an important gap by building strong partnership opportunities between funded entities (academic and/or private) and leading pharma organizations. These links are fundamental to the success of any SME evolving in the life sciences industry.

FILLING THE GAP

PUBLIC FUNDS FOR ACADEMIC

RESEARCH

MARKET

PRIVATE INVESTMENTS

Discovery ClinicalTranslational research Pre-clinical

• Monitoring drug-induced cardiotoxicity using state-of-the-art nanoengineering technology. (J. Maynes, Hospital for Sick Children) in partnership with Ontario Centres of Excellence• Targeting the immunosuppressive functions of galectins using dimer interfering peptides. (Y. Saint-Pierre, INRS)• Addressing chemotherapy-induced neuropathy using a sensory nerve stem cell technology. (M. Bhatia, McMaster University) in partnership with Ontario Centres of Excellence.

4. An established footprint throughout CanadaSince 2012, CQDM has worked actively to broaden its activities across Canada by providing incentives to Quebec researchers to collaborate with other provinces.

• With the new projects funded in 2016, CQDM can now truly claim to have an established footprint throughout Canada • A collaboration outside Quebec is included in 17 of its outstanding projects• In the last year, up to 68% of the submitted applications involved inter-provincial research collaborations, clearly highlighting the growing interest in CQDM’s funding by Canadian researchers.

In 2016, CQDM has funded 9 new projects involving 27 researchers from 12 institutions (8 public and 4 private) across Canada, all of which address important unmet needs in drug discovery

IN 2016

9 NEW PROJECTS

$5.6M IN FUNDING

27 NEW RESEARCHERS FUNDED

12 INSTITUTIONS

FOOTPRINT IN CANADA

5HIGHLIGHTS 2016

1. Delivering excellence…With its 6 completed projects in 2016 and 32 ongoing projects, CQDM continues to foster outstanding technological innovations that produce tangible results benefiting all stakeholders, including:

• Robust validation of a unique prototype for predicting immunogenicity of biological therapeutics and detecting anti-drug antibodies. (P. Vermette, Université de Sherbrooke)• Successful demonstration of gene delivery in the retina using lasers and gold nanoparticles. (M. Meunier, Polytechnique Montréal)• Exciting results confirming ability to cross the blood-brain barrier and reduce β-amyloid levels in the brain, paving the way for human clinical trials. (N. Yoganathan, KalGene Pharmaceuticals)• Development of an innovative high throughput assay to identify molecules that target mutant protein-protein interactions in cancer using the MaMTH technology. (I. Stagljar, University of Toronto)• Solid proof of concept of a revolutionary approach to efficiently deliver anti-cancer drugs to hypoxic regionsin tumors using magneto-aerotactic bacteria. (S. Martel, Polytechnique Montréal) • Early results of a pilot study demonstrating game-changing retinal detection of amyloid β plaques in Alzheimer’s disease patients. (J.P. Soucy, McGill University).

… and building on itCQDM facilitated the maturation of technologies that are fueling the growth of 34 SMEs, including:

• Biospective broadened its catalogue of services with the development of new and unique mouse models for Alzheimer’s disease based on the expression of human Tau and APP, in collaboration with Merck and Pfizer• Photon etc. is fine-tuning a state-of-the art hyperspectral camera to develop new promising applications in early screening of breast cancer• Diazon Pharmaceuticals has provided $2.5M to apply the results generated by G. Shore and proceed with a phase II proof of concept for an anti-cancer molecule based on synthetic lethality• PulmoScience is poised to secure major funding or a partnership in order to advance the development of a non-invasive imaging agent used to detect pulmonary hypertension further to the successful phase II study funded by CQDM and headed by J. Dupuis• Domain Therapeutics has set its sights on developing and commercializing M. Bouvier’s G protein-coupled receptor biosensor technology.

2. A first Canada-Germany collaborative project addressing protein trafficking diseases CQDM and AiF, an agency of the German government, are co-funding a $1M innovative project headed byDavid Y. Thomas (McGill University, Montreal, Canada) and Bert Klebl (Lead Discovery Center, Dortmund, Germany). • The researchers are combining their unique expertise to develop an integrated screening platform to study the pharmacology of the endoplasmic reticulum and protein trafficking diseases• This platform will identify new targets and off-target effects of known drugs, and potentially undiscovered ones, for indications such as Alzheimer’s disease, cancer and diabetes.

3. Initiation of 9 innovative and potentially game-changing projects for a total of $5.6M in funding CQDM has the means to push translational research to the next level, thanks to the substantial financial leverage provided by its co-funding partners (Brain Canada and Ontario Centres of Excellence).

• Targeting elusive protein-protein interactions through a public-private partnership bolstering Proteorex Therapeutics’ innovative small molecule fragments-based platform. (R. Batey, University of Toronto) in partnership with Ontario Centres of Excellence• A patient-derived neuronal cell-based screening platform to develop drugs for Parkinson’s disease and amyotrophic lateral sclerosis. (E. Fon, McGill University) in partnership with Brain Canada • Breaking the cold chain of vaccine transportation by developing thermally stable spray dried vaccines. (M. Thompson, McMaster University) in partnership with Ontario Centres of Excellence• Predicting the efficacy of new immunotherapies using a flow cytometry platform. (D. Larocque, PAIRimmune Inc.) • A protein trafficking-related screening platform to identify drugs against cancer, neurological and metabolic diseases. (D. Y. Thomas, McGill University and B. Klebl, Lead Discovery Center, Germany) in partnership with the Government of Germany and AiF• A HTS platform to identify drugs against RNA-binding proteins involved in brain disorders and diseases. (J.M. Beaulieu, University of Toronto) in partnership with Brain Canada

4

76

902researchers

9pharma

members 22projects completed

8start-ups

36products

$43M engaged $29M

co-funding

120 mentors

59 funded projects

686 high-level jobs

74 organizations

40 public

73% integration in industry

success rate85%

34 SMEs

CQDM BY THE NUMBERS

Coming from the United States and Europe, these mentors are the ultimate end users of the tools and technologies that are being developed. They offer valuable expertise and resources to help in the development of the projects, ensure that CQDM’s funded research is aligned with the needs of the industry and help in the integration of these enabling technologies in pharma R&D.

To date, 120 mentors have been involved in CQDM’s projects. These win-win collaborations have proven to be invaluable to the researchers and the mentors, and fostered many long-term partnerships.

One of the innovative aspects of CQDM is its unique mentorship program which connects funded researchers with senior scientists from CQDM’s pharma partners

MENTORSHIP PROGRAM

“

“

”

”

Mentorship from senior partners in the pharmaceutical industry have made our Explore project evolve much more quickly and intelligently into a commercially viable technology by identifying critical hurdles to validate the technology and accelerate the path to the clinic. This is a great collaborative model for overcoming the challenges of taking academic research into the commercial sphere.

The mentorship program is the distinguishing feature and jewel of CQDM. We have benefited immensely from the opportunity to engage with senior scientists from pharma as the end users of our technology. Their critical feedback and guidance early in our project led to significant improvements in our technology and has provided us with new insights on how to position our technology for rapid translation and direct impact in drug discovery.

- Derrick Gibbings, University of Ottawa

- Craig Simmons, University of Toronto

98

“

”

The funds were injected at a pivotal early development stage of this technology which uses special bacteria acting as computer-controlled nanobots to deliver drugs to the core of tumors. I was particularly happy and surprised by CQDM’s decision to fund this project at a time when most people believed it was pure science fiction. With CQDM sharing our vision and investing in this new idea, we finally had the means to make it a reality that I sincerely hope will significantly improve cancer treatments and offer new hope for many future patients.

Some 55% of computer-guided drugs carried bythese nanorobotic agents reach active tumor cells versus only 1-2% with standard systemic chemotherapy, providing a powerful delivery approach to increase therapeutic efficacy of most anti-cancer drugs by orders of magnitude

$1.9M OVER 3 YEARS

Investigators: Sylvain Martel (Polytechnique Montréal), Michael Atkin (Syzent Partners), Gerald Batist, Nicole Beauchemin, Danuta Radzioch, Maryam Tabrizian and Te Vuong (McGill University), Louis Gaboury and Michel Lafleur (Université de Montréal)

FROM FICTION TO REALITY: DROVES OF GUIDED NANOBOTS SEEK AND DESTROY CANCEROUS TUMORS

At a glance Professor Martel’s team accomplished a spectacular breakthrough in the fight against cancer by steering potent but toxic therapeutics at the core of solid tumors without affecting surrounding healthy tissues. This feat was accomplished by using magneto-aerotactic bacteria harnessed to act as natural nanobots weaponized with anti-cancer drugs. Once injected, the nanobots migrate to hypoxic regions of tumors reaching active cancer cells known to be resistant to most treatments.

Accomplishments An article published in Nature Nanotechnology reported a solid proof of concept for anti-tumor nanobots in a colorectal cancer model showing strong accumulation intumor cores followed by significant decrease in tumor size. Bolstered by this extraordinary breakthrough funded mainly by CQDM, Professor Martel secured substantial newinvestments ($4.6M) to setup an interventional room where a first human-scale magnetotactic platform will be used to guide these drug-loaded bacterial nanobots. This unique platform will help transpose this game-changing technology to the clinic.

Future impactsThese accomplishments position Professor Martel’s team and Quebec at the forefront of a new era of precision medicine. Should the procedure prove safe and effective in humans, the now functional infrastructure will enable cancer patients to fully benefit from these powerful new targeted technologies. A key strength of this platform is its adaptability to all existing anti-cancer drugs, making it a formidable new addition to the arsenal to fight cancer.

8SUCCESS STORIES

- Sylvain Martel

CQDM recognized the disruptive potential of the technology and provided the funding that allowed this team of visionaries to reach their goal to revolutionize cancer treatment

“

”

The CQDM grant allowed us to assemble a world-class team of Canadian clinicians and scientists to develop a novel disease-modifying Alzheimer’s therapeutic. KalGene will be conducting phase I studies at McGill in 2017.

• About 564,000 Canadians suffer from dementia, 338,000 of which have Alzheimer’s disease (AD) • By 2031, the number of AD patients is expected to increase by 66%, reaching 563,000• About 60% of people in long-term care facilities have AD• There is currently no cure for AD.

$1.5M OVER 3 YEARSin collaboration with Brain Canada and the Ontario Brain Institute

Investigators: Nathan Yoganathan, John Gillard (KalGene Pharmaceuticals), Danica Stanimirovic, Balu Chakravarthy (NRC), Louis Collins, Jean-Paul Soucy (McGill University), Pedro Rosa-Neto (Douglas Hospital Research Centre) and Michael Waterston (Centre for Imaging Technology Commercialization)

KALGENE FIGHTS ALZHEIMER’S DISEASE USING A TECHNOLOGY TO DELIVER THERAPEUTICS ACROSS THE BLOOD-BRAIN BARRIER

At a glance KalGene is developing a novel Alzheimer’s therapeutic capable of crossing the blood-brain barrier (BBB) and is demonstrating that their lead compound KAL-ABP-BBB is active in humans. This innovative therapeutic is a fusion of a peptide that binds the toxic form of β-amyloid and an antibody that acts as a Trojan horse to deliver the peptide into the brain. The team is also developing imaging agents to follow the physiological distribution of their drug.

CQDM’s funding fills an important gap in reaching an essential value creation milestone and in derisking the technology necessary to raise funding from venture capital

Accomplishments The team has demonstrated that KAL-ABP-BBB can be delivered into brain tissue when injected in the blood of transgenic animals harboring symptoms of Alzheimer’s disease due to the expression of a mutated form of human β-amyloid peptides in their brain. The brain and cerebrospinal fluid exposure of KAL-ABP-BBB in animals was 25 fold higher than a typical antibody. Although the goal of these experiments was to demonstrate enhanced BBB crossing of KAL-ABP-BBB, they also revealed a significant reduction of β-amyloid plaques in the brain of transgenic animals.

Future impactsBuilding on these results, KalGene is raising funds toperform its first human clinical trial involving 20 Alzheimer’s disease patients. If the results of the human trial are consistent with preclinical data, it will be the first clinical demonstration of improved brain delivery of an Alzheimer’s disease therapeutic using BBB Trojan horse technology.

SUCCESS STORIES

- Nathan Yoganathan

1110

“

”

Beyond the financial support to our clinical development efforts brought by CQDM, the Focus on Brain program allowed Optina Diagnostics to construct a multi-center clinical trial reaching out to a large patient population supported by a collaboration with internationally renowned researchers from Ontario and Quebec.

$1.5M OVER 3 YEARS in collaboration with Brain Canada and Ontario Brain Institute

Investigators: Jean-Paul Soucy (McGill University), Sandra Black (Sunnybrook Research Institute), Frédéric Lesage (Polytechnique Montréal), Jean-Philippe Sylvestre (Optina Diagnostics), Pedro Rosa-Neto, Serge Gauthier (Douglas Hospital Research Centre), and Sylvain Beaulieu (Hôpital Maisonneuve-Rosemont)

CRUCIAL FUNDING FOR A START-UP DEVELOPING AN EARLY DIAGNOSTIC TOOL FOR ALZHEIMER’S DISEASE USING THE EYE AS A NATURAL WINDOW TO THE BRAIN

At a glance This project aims to develop and validate a hyperspectral imaging platform that detects amyloid β plaques in the retina which are a surrogate marker of Alzheimer’s disease in the brain. Achieving simple, robust and non-invasive early diagnosis of Alzheimer’s disease with Optina’s new camera will revolutionize both Alzheimer’s disease drug development and clinical management of patients.

Fill the gap This large and ambitious project structured as a truepublic-private partnership within the Quebec-Ontario corridor is vital for Optina Diagnostics Inc. This Montrealstart-up is entirely focused on developing and commercializing analytical services from this imaging technology. The funding allows Optina to proceed with a first and robust clinical proof of concept of the device, which is otherwise very difficult to fund due in largepart to the paucity of private investors at this early stage of both corporate and technological development. Reaching this important milestone will position Optina favorably to raise the necessary capital to deploy the instrument for commercialization and to seize the already huge and expanding untapped market for Alzheimer’s disease diagnosis.

Accomplishments/Future impacts The team is currently making great strides and has already reached a major milestone in completing the prototype, including state-of-the-art software and hardware, and regulatory approvals required to image patients. The prototype is now being used in a pilot feasibility studyin humans which will lead to the next phase of the project,a large multi-center clinical validation of the diagnostic tool. Early detection of at-risk patients with Optina’s validated technology will radically transform clinical trial design and promote the emergence of new and efficient treatments to address this 21st century plague.

10SUCCESS STORIES

- Jean-Paul Soucy

“

”

The funding from CQDM has allowed us to take our unique technology to the next level and develop a high-throughput drug screening technology that targets disease-associated membrane proteins in their native environment, a notoriously challenging achievement. This screeningplatform could dramatically increase the number of candidate drugs for new treatments against a wide range of diseases including cancers, neurological disorders and cystic fibrosis.

• Many diseases cannot be treated due to a lack of appropriate therapeutic targets• Inhibiting protein-protein interactions could lead to the generation of up to 60,000 new targets (most of them still untapped) for conditions such as cancer and neurodegenerative diseases.

$300K OVER 2 YEARS in collaboration with Ontario Centres of Excellence

Investigator: Igor Stagljar (University of Toronto)

INHIBITING PROTEIN-PROTEIN INTERACTIONS: AN INNOVATIVE PLATFORM TO IDENTIFY HUNDREDS OF NEW THERAPEUTIC TARGETS AND THE DRUGS THAT INTERFERE WITH THEM

At a glance Identifying protein-protein interactions (PPIs) in human cells is critically important in understanding the function of cells and developing new treatments for diseases. However, this process presents numerous challenges, particularly when dealing with PPIs involving membrane proteins. To help address these challenges, Professor Stagljar and his team have developed Mammalian Membrane Two-Hybrid (MaMTH), a disruptive technology that can not only identify PPIs, but also drugs that could inhibit their functions. MaMTH relies on a tagged membrane bait protein that can rapidly be screened with numerous prey interactors simultaneously and in a natural cellular context. Once a prey and the bait interact, a fluorescent or luminescent protein is produced and easily detected. This read-out can also be used to help isolate putative drugs that interfere with PPIs.

Accomplishments CQDM is funding this high-risk high-reward project because of the immense potential of the technology and its capability to identify lead molecules for the development of new drugs. A first proof of concept has been made with the Epidermal Growth Factor Receptor (EGFR), which is often mutated in cancer cells. The team has discovered several small molecules that inhibit only mutant EGFR interactions without affecting the normal EGFR protein, thus leading to promising drugs with potentially less unwanted side effects than currently available drugs.

Future impactsBuilding on these results, Professor Stagljar will develop this innovative approach as a powerful discovery engine to unveil additional PPIs involved in cancer and neurodegenerative diseases. Discussions are in progress to create a start-up company that will exploit the technology to initiate a development program in oncology.

SUCCESS STORIES

- Igor Stagljar

Neurodegeneration & Mental HealthBeaulieu Identifying drugs against RNA-binding proteinsBedell Animal models for Alzheimer’sBedell Animal models for Parkinson’sBlais-Ouellette Protein-protein interactions in CNSDi Paolo Parkinson’s early diagnosis and treatmentFon Drug discovery for Parkinson’s disease and amyotrophic lateral sclerosisHoge Diagnostic for Alzheimer’s diseaseHutchison New shuttle molecules to cross the blood-brain barrierMaziade ERG biomarkers for psychiatric disordersPawliszyn Chemical biopsies in the brainSoucy Early diagnostic of Alzheimer’s disease through the eyes

Wen Zebrafish drug screening platformYoganathan Delivering therapeutics across the human blood-brain barriervan Meyel A glutamate biosensor platform for brain diseases

OncologyAffar Selective inhibitors of the ubiquitin proteasomeBabak Targeted synthetic lethality screens Chelsky New targets for neuroendocrine tumorsKremer Screening tools using circulating tumor cellsMes-Masson Microfluidic platform for cancer therapyPark Stromal biomarkers for breast cancerPerrée Functional and genomic profiling for cancer therapyShore Synthetic lethality platform and oncologySaint-Pierre Anti-galectins to fight cancerWrana Precision medicine platform in cancer

DiabetesEscher Real-time in vivo analyte measurementParamithiotis Biomarkers for ß-cells diabetesVermette Bioartificial pancreas screening platform

PORTFOLIO OF PROJECTS

BIOINFORMATICSSCREENING PLATFORMS

ONCOLOGY

IMAGING TECHNOLOGIES

NEURODEGENERATION & MENTAL HEALTH

12 13

Infection & ImmunityBergeron Resistance to antibiotics Larocque Efficacy assessment of new immunotherapiesRichards Somatic mutations of reacting T cells in inflammatory diseasesThompson Thermally stable spray dried vaccinesVézina Discovery platform for VLP vaccine antigens

Drug DeliveryGibbings Exosomes for siRNA deliveryMartel Magnetically guided drug delivery platform Meunier Nanoparticle-based drug delivery in the eyeSimpson Gene therapy in the eyes

Imaging TechnologiesBouvier Engineered mice for GPCR studiesDupuis Imaging biomarkers for pulmonary hypertensionMermut Live-cell imaging of protein-protein interactions

BiologicsCoull Orally bioavailable macrocyclesSulea Extended half-lives of small biologicsVermette Assay for immunogenicity detectionYudin Macrocycles library

Screening PlatformsBatey Small molecules against protein-protein interactionsBerthod Tissue-engineered human skinBhatia iPS sensory neurons for chemo-induced and neuropathic painBouvier Biosensors for GPCR signalingGiguère In vivo nuclear receptor screening platformGötte Phage-based screening of antiviralsHébert Dynamic response to GPCR drugsKrause In vivo nuclear receptor screening platform 2.0Maynes Lab-on-chip assessment of cardiotoxicityPiñeyro Biosensors for ion channelsSimmons Microfluidic hepatotoxicity screensStagljar Identifying and acting on protein-protein interactionsThomas Toolkit for protein trafficking diseases

BioinformaticsCorbeil Machine learning for screening peptidesNajmanovich Molecular interaction fields detection platformPurisima In silico predictivity of mAb affinity

BIOLOGICS

INFECTION & IMMUNITY

DRUG DELIVERY

DIABETES

14

The statement of financial position as at March 31, 2016 and 2015 and statement of operations for the years ended March 31, 2016 and 2015 that follow are provided as illustrative summaries only and are not intended to replace the full financial statements of CQDM. These full financial statements were audited and reported on July 14, 2016 by KPMG LLP, Chartered Accountants.

$ 11,124,058

323,87111,447,929

10,143,23621,591,165

2,019,44619,571,71921,591,165

— 21,591,165

$ 4,383,161

397,4174,780,578

4,262,204518,374

4,780,578

—

$ 18,739,084

1,350,70720,089,791

3,936,275 24,026,066

1,318,341 22,707,725 24,026,066

— 24,026,066

$ 3,647,392

452,9684,100,360

3,652,181448,179

4,100,360

—

ASSETSCash and short-term investmentsOther current assetsTotal

Investments and other long-term assetsTotal

LIABILITIESAccounts payable and other current liabilities Long-term deferred contributionsTotal

NET ASSETSUnrestrictedTotal

REVENUESContributions Other incomeTotal

EXPENSESProject expenditures and other mission fulfillment expenses Administrative and governanceTotal

Excess of revenues over expenses

Statement of financial position As at March 31, 2016 and 2015

Statement of operationsFor years ended March 31, 2016 and 2015

2016

2016

2015

2015

FINANCIAL SUMMARY

PHARMA MEMBERS

GOVERNMENTS

We are proud to be able to count on 9 of the world’s leading pharmaceutical companies as members. We also have the support from the governments of Quebec and Canada. The value of their direct and indirect support is simply immeasurable!

Founding members

Program specific members

CONTRIBUTIONS 15

STRATEGIC ORIENTATION COMMITTEE

Steven Xanthoudakis (Chairman)Director, Business Development & Licensing, Merck Canada

André DarveauDean, Faculty of Sciences and Engineering, Université Laval

Christian FibigerAssistant Dean, Research, Faculty of Medicine, University of British Columbia

Diane GosselinPresident and Chief Executive Officer, CQDM

Daniel HétuManaging Director, Lumira Capital

Mark Lim Program Officer, Diagnostics, Integrated Development and Global Health, Gates Foundation

Patrice RoyRegional Director, Medical Affairs, Pfizer Canada

Observers

Monika MichalskaSenior Program Manager, Networks of Centres of Excellence of Canada

Catherine RichardAdvisor, Industrial Partnerships, Quebec Ministry of Economy, Science and Innovation (MESI)

EXPLORE ADVISORY COMMITTEE

Patrice Roy (Chairman)Regional Director, Medical Affairs, Pfizer Canada

Luc BoulaySenior Clinical Research Scientist, Neuroscience, Eli Lilly Canada

Anders BrunmarkDirector, External Innovation, Discovery Sciences, Janssen R&D

Michael DraperSenior Director, Scouting and Partnering, Sanofi R&D

Diane GosselinPresident and Chief Executive Officer, CQDM

Cyrille KuhnExecutive Director, Research Networking & Strategic Planning, Boehringer Ingelheim Pharmaceuticals, USA

Amyn SayaniDirector, R&D Alliances, GSK Canada

Aamir ShamimActing CSO & VP Scientific Affairs, Novartis Canada

Steven XanthoudakisDirector, Business Development & Licensing, Merck Canada

CORPORATE INFORMATION 1716

BOARD OF DIRECTORS

Richard Fajzel (Chairman)Chief Executive Officer, Exactis Innovation

Jennifer ChanVice President, Policy and Communications, Merck Canada

Max Fehlmann President and Chief Executive Officer, NEOMED

Michel GoldmanDirector, Institute for Interdisciplinary Innovation in Healthcare, Université Libre de Bruxelles

Diane GosselinPresident and Chief Executive Officer, CQDM

Raphael HofsteinPresident and Chief Executive Officer, MaRS Innovation

Vassilios Papadopoulos Dean, John Stauffer Dean’s Chair in Pharmaceutical Sciences, University of Southern California

Ken Pastor General Partner, CTI Capital

Louise Proulx Chief Development Officer, Therillia Development Company

Jorge PuenteCo-Founder and Managing Partner, Pleasanton Pharma Ventures

Uwe SchoenbeckChief Scientific Officer, External Research & Development Innovation (ERDI), Pfizer

Ali TehraniCo-founder, President and Chief Executive Officer, Zymeworks

Patrick J. WierSenior Vice President, In Vitro/In Vivo Translation Platform, GSK

Observers

Martin HouleDirector, Industrial Partnerships, Quebec Ministry of Economy, Science and Innovation (MESI)

Monika MichalskaSenior Program Manager, Networks of Centres of Excellence of Canada

CORPORATE INFORMATION

BOARD OF DIRECTORS

STRATEGIC ORIENTATIONCOMMITTEE

EXPLOREADVISORY

COMMITTEE

1818THE TEAM

Team

Diane GosselinPresident and Chief Executive Officer

Mario ChevretteVice President, Scientific Affairs

Michael BridgesVice President, Finance and Administration

Marc ThibaultDirector of Programs, Scientific Affairs

Mathieu PerréeProject Manager, Scientific Affairs

Eugénie Bergeron-CôtéCommunications Advisor

Jennifer SaleebExecutive Assistant

19

WWW.CQDM.ORG7140, Albert-Einstein, suite 100Montreal, Quebec, Canada H4S 2C1 T: +1 (514) 766-6661 E-mail: info@cqdm.org